Guardant Health’s (GH) Buy Rating Reaffirmed at Guggenheim

Guardant Health (NASDAQ:GH)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research report issued on Wednesday,Benzinga reports.

A number of other equities analysts have also recently commented on GH. JPMorgan Chase & Co. boosted their price target on Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Leerink Partners lowered their price target on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Sanford C. Bernstein lowered their price target on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a report on Wednesday, October 30th. Finally, The Goldman Sachs Group upped their target price on Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Sixteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Guardant Health currently has a consensus rating of “Buy” and an average target price of $41.81.

Guardant Health Price Performance

Shares of NASDAQ GH opened at $48.60 on Wednesday. Guardant Health has a fifty-two week low of $15.81 and a fifty-two week high of $49.86. The stock has a market capitalization of $6.01 billion, a PE ratio of -11.46 and a beta of 1.28. The business has a fifty day moving average price of $34.89 and a two-hundred day moving average price of $29.39.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The business had revenue of $191.48 million for the quarter, compared to analyst estimates of $170.49 million. During the same period last year, the firm posted ($0.73) EPS. Guardant Health’s quarterly revenue was up 33.9% on a year-over-year basis. On average, equities analysts expect that Guardant Health will post -3.44 EPS for the current year.

Insider Buying and Selling at Guardant Health

In related news, Director Musa Tariq sold 2,320 shares of the company’s stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $35.00, for a total transaction of $81,200.00. Following the sale, the director now owns 2,676 shares in the company, valued at $93,660. This represents a 46.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Meghan V. Joyce sold 2,896 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total value of $86,590.40. Following the sale, the director now owns 7,648 shares in the company, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,548 shares of company stock worth $179,782. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Guardant Health

Institutional investors and hedge funds have recently made changes to their positions in the business. R Squared Ltd bought a new position in Guardant Health in the fourth quarter worth approximately $26,000. JNBA Financial Advisors bought a new position in Guardant Health in the third quarter worth approximately $26,000. Ashton Thomas Securities LLC bought a new position in Guardant Health in the third quarter worth approximately $34,000. Quarry LP bought a new position in Guardant Health in the second quarter worth approximately $44,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Guardant Health in the second quarter worth approximately $71,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.